VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
TMDX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
TMDXTransMedics Group, Inc.
$70.78$2.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksTMDXEarnings History

TMDX logoTransMedics Group, Inc. (TMDX) Earnings History

Profitable

10 years of earnings data (2016–2025) · Positive TTM net income

TTM Net Income
$152M
● Profitable
TTM EPS (Diluted)
$3.73
Per share, diluted
YoY EPS Growth
+382.2%
Excellent
Net Margin
31.4%
After-tax profitability
EPS Growth Rate (CAGR)
1Y+382.2%
3YN/A
5YN/A
10YN/A
Operating Margin17.9%
Gross Margin59.9%
Return on Equity54.2%
Return on Assets20.3%
Record Annual Net Income$190MFY2025
Record Quarterly EPS$2.59Q4 2025
Consecutive Profitable Years2years
Q2 2026
Net Income$15M
EPS (Diluted)$0.41
YoY Growth+382.2%Excellent
QoQ Growth+100.7%Excellent

Loading earnings history...

TransMedics Group, Inc. (TMDX) Earnings Overview

As of October 17, 2026, TransMedics Group, Inc. (TMDX) reported trailing twelve-month net income of $152M, reflecting +382.2% year-over-year growth. The company earned $3.73 per diluted share over the past four quarters, with a net profit margin of 31.4%.

Looking at the long-term picture, TMDX's historical earnings data spans multiple years. The company achieved its highest annual net income of $190M in fiscal 2025, representing a new all-time high.

TransMedics Group, Inc. maintains industry-leading profitability with a gross margin of 59.9%, operating margin of 17.9%, and net margin of 31.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →

Compared to peers including AVXL (-$32M net income), STVN ($134M net income, 11.8% margin), NVCR (-$149M net income, -20.8% margin), TMDX has comparable earnings metrics. Compare TMDX vs AVXL →

TMDX Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
TMDX logoTMDXCurrent
$152M$3.7331.4%54.2%+382.2%—
AVXL logoAVXL
-$32M$-0.35--43.1%-3.8%
STVN logoSTVN
$134M$0.4911.8%9.3%+14.0%
NVCR logoNVCR
-$149M$-1.28-20.8%-38.9%+21.8%
LIVN logoLIVN
$189M$3.35-17.5%-19.2%-483.6%
ATRC logoATRC
$11M$0.21-2.1%-2.4%+74.7%
Best in group
Lowest in group

TMDX Historical Earnings Data (2016–2025)

10 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$190M+436.6%$109M$4.8731.4%17.9%
2024$35M+241.7%$37M$1.018.0%8.5%
2023-$25M+30.9%-$29M$-0.77-10.4%-11.9%
2022-$36M+18.1%-$31M$-1.23-38.8%-33.6%
2021-$44M-53.8%-$39M$-1.60-146.1%-130.3%
2020-$29M+14.3%-$26M$-1.16-112.1%-102.9%
2019-$34M-41.2%-$30M$-2.36-142.1%-125.4%
2018-$24M-14.1%-$20M$-1.23-182.5%-155.5%
2017-$21M+13.5%-$20M$-1.44-271.0%-265.8%
2016-$24M--$23M$-1.66-387.6%-370.2%

Download Data

Export TMDX earnings history in CSV or JSON format

Free sign-in required to download data

Consensus & Technical Research Suite
Open TMDX Terminal

TMDX Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TMDX — Frequently Asked Questions

Quick answers to the most common questions about buying TMDX stock.

What is TMDX earnings per share (EPS)?

TMDX trailing twelve-month (TTM) diluted EPS is $3.73, reflecting +382.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.

What is TransMedics Group, Inc.'s net income?

TransMedics Group, Inc. (TMDX) trailing twelve-month net income is $152M as of 2025. Earnings grew +382.2% year-over-year. TransMedics Group, Inc. has been profitable for 2 consecutive years.

Is TMDX profitable?

Yes, TMDX is profitable with a TTM net income of $152M and a net profit margin of +31.4%. TransMedics Group, Inc. has generated profits for 2 consecutive years.

What is TMDX's earnings growth rate?

TMDX compound annual EPS growth rates (CAGR): 1-Year: +382.2%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.

What are TMDX's profit margins?

TransMedics Group, Inc. net profit margin is +31.4%, operating margin is +17.9%, and gross margin is +59.9%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +54.2%.

Is TMDX growing earnings?

Yes, TMDX earnings are accelerating — EPS growth of +382.2% exceeds the 5-year CAGR of N/A. TTM net income reached $152M. Earnings momentum is strengthening.

What was TMDX's best earnings year?

TransMedics Group, Inc.'s highest annual net income on record is $190M, achieved in fiscal year 2025. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.

What were TMDX's earnings last quarter?

TMDX's most recent reported quarter was Q2 2026. Net income was $15M with diluted EPS of $0.41. For a full breakdown of all quarters, see the quarterly earnings table on this page.

TMDX Earnings Over Time (2016–2025)

Net income & EPS — annual and quarterly view